Department of Dermatology, Harrogate and District NHS Foundation Trust, Lancaster Park Road, Harrogate, HG2 7SX, UK.
Department of Dermatology, Penn State University, Hershey, PA, USA.
Am J Clin Dermatol. 2021 Mar;22(2):159-171. doi: 10.1007/s40257-020-00564-6.
Acne (syn: acne vulgaris) ranks as the most common inflammatory dermatosis treated worldwide. Acne typically affects adolescents at a time when they are undergoing maximum physical and social transitions, although prevalence studies suggest it is starting earlier and lasting longer, particularly in female patients. According to global burden of disease studies, acne causes significant psychosocial impact. Hence, identifying mechanisms to accurately measure the impact of the disease is important. Adopting an approach to harmonize and standardize measurements is now recognized as an essential part of any clinical evaluation and allows for better comparison across studies and meta-analyses.
The Acne Core Outcome Research Network (ACORN) has identified relevant domains as part of a core outcome set of measures for use in clinical studies. One of these is health-related quality of life (HRQoL). The aim of this systematic review was to provide information to inform the identification of the impacts most important to people with acne.
A synthesis of available evidence on acne impacts was constructed from a systematic review of the literature, with searches conducted in the MEDLINE, EMBASE and PsychInfo databases.
We identified 408 studies from 58 countries using 138 different instruments to detect the impacts of acne. Four of the five most commonly used instruments (Dermatology Life Quality Index [DLQI], Cardiff Acne Disability Index [CADI], Acne Quality of Life scale [Acne-QoL], Hospital Anxiety and Depression Scale [HADS] and Skindex-29) do not identify specific impacts but rather quantify to what extent acne affects HRQoL. Other studies identified one or more impacts using open-ended questions or tailor-made questionnaires.
This review serves as a rich data source for future efforts by groups such as ACORN (that include patients and health care providers) to develop a core set of outcome measurements for use in clinical trials.
痤疮(同义词:寻常痤疮)是全球治疗最多的最常见炎症性皮肤病。痤疮通常发生在青少年经历最大身体和社会转变的时候,尽管流行性病学研究表明,痤疮发病时间更早且持续时间更长,尤其是女性患者。根据全球疾病负担研究,痤疮会造成显著的心理社会影响。因此,确定能够准确衡量疾病影响的机制非常重要。目前已经认识到,采用协调和标准化测量方法是任何临床评估的重要组成部分,有助于跨研究和荟萃分析进行更好的比较。
痤疮核心结局研究网络(ACORN)已确定相关领域作为临床研究中使用的核心结局测量集的一部分。其中之一是健康相关生活质量(HRQoL)。本系统评价旨在提供信息,以确定对痤疮患者最重要的影响。
通过对 MEDLINE、EMBASE 和 PsychInfo 数据库进行检索,对文献进行系统评价,构建了痤疮影响的现有证据综合。
我们从 58 个国家的 408 项研究中确定了使用 138 种不同工具来检测痤疮影响的研究。使用最广泛的 5 种工具中的 4 种(皮肤病生活质量指数[DLQI]、加的夫痤疮残疾指数[CADI]、痤疮生活质量量表[Acne-QoL]、医院焦虑抑郁量表[HADS]和 Skindex-29)无法确定特定影响,而只是量化了痤疮对 HRQoL 的影响程度。其他研究则使用开放式问题或定制问卷确定了一个或多个影响。
本综述为 ACORN 等团体(包括患者和医疗保健提供者)未来开发用于临床试验的核心结局测量集的努力提供了丰富的数据源。